Ja Seo Koo1,2, Seong Hwan Moon3, Hankil Lee4,5, Sohee Park5, Yun Mi Yu6, Hye-Young Kang6. 1. Department of Pharmaceutical Medicine and Regulatory Sciences, Colleges of Medicine and Pharmacy, Yonsei University, Incheon, South Korea. 2. Department of Medical Affairs, Sanofi-aventis Korea Co., Ltd., Seoul, South Korea. 3. Department of Orthopedic Surgery, College of Medicine, Yonsei University, Seoul, South Korea. 4. Institute of Health Services Research, Yonsei University, Seoul, South Korea. 5. Graduate School of Public Health, Yonsei University, Seoul, South Korea. 6. College of Pharmacy, Yonsei Institute of Pharmaceutical Sciences, Yonsei University, Incheon, South Korea.
Abstract
INTRODUCTION: The Korean National Health Insurance revised its reimbursement criteria to expand coverage for anti-osteoporotic drug treatments in 2011 (expanding diagnostic criteria and the coverage period for anti-osteoporotic therapy) and 2015 (including osteoporotic fracture patients regardless of bone mineral density). We examined whether the two revisions contributed to an increase in the prescription rates of anti-osteoporotic drugs in Korea. METHODS: We used the Health Insurance Review and Assessment Service-National Patient Sample data from 2010 through 2016. A segmented regression analysis of interrupted time series was performed to assess changes in the monthly prescription rates of anti-osteoporotic drugs among women aged 50 or older, defined as the proportion of elderly women prescribed with anti-osteoporotic drugs. RESULTS: Both the levels (i.e., abrupt jump or drop) and the trends (i.e., slope) of the prescription rates of anti-osteoporotic drugs in the general population, osteoporotic patients, and osteoporotic fracture patients showed no significant changes after the first revision. However, there was a significant increase in the trends in the general population (β = 0.0166, p = 0.0173) and in osteoporotic patients (β = 0.1128, p = 0.0157) after the second revision. Women aged 65 to 79 years were the most significantly increased group in terms of the treatment proportion after the second revision because the trend was significant after the second revision in all three study populations (β = 0.0300, 0.1212, 0.1392, respectively; p < 0.05). CONCLUSIONS: Although the two revisions expanded reimbursement coverage, only the second revision on reimbursing based on osteoporotic fracture regardless of bone mineral density was associated with increasing the proportion of post-menopausal women being treated with anti-osteoporotic drugs.
INTRODUCTION: The Korean National Health Insurance revised its reimbursement criteria to expand coverage for anti-osteoporotic drug treatments in 2011 (expanding diagnostic criteria and the coverage period for anti-osteoporotic therapy) and 2015 (including osteoporotic fracturepatients regardless of bone mineral density). We examined whether the two revisions contributed to an increase in the prescription rates of anti-osteoporotic drugs in Korea. METHODS: We used the Health Insurance Review and Assessment Service-National Patient Sample data from 2010 through 2016. A segmented regression analysis of interrupted time series was performed to assess changes in the monthly prescription rates of anti-osteoporotic drugs among women aged 50 or older, defined as the proportion of elderly women prescribed with anti-osteoporotic drugs. RESULTS: Both the levels (i.e., abrupt jump or drop) and the trends (i.e., slope) of the prescription rates of anti-osteoporotic drugs in the general population, osteoporoticpatients, and osteoporotic fracturepatients showed no significant changes after the first revision. However, there was a significant increase in the trends in the general population (β = 0.0166, p = 0.0173) and in osteoporoticpatients (β = 0.1128, p = 0.0157) after the second revision. Women aged 65 to 79 years were the most significantly increased group in terms of the treatment proportion after the second revision because the trend was significant after the second revision in all three study populations (β = 0.0300, 0.1212, 0.1392, respectively; p < 0.05). CONCLUSIONS: Although the two revisions expanded reimbursement coverage, only the second revision on reimbursing based on osteoporotic fracture regardless of bone mineral density was associated with increasing the proportion of post-menopausal women being treated with anti-osteoporotic drugs.
Authors: Robert A Adler; Ghada El-Hajj Fuleihan; Douglas C Bauer; Pauline M Camacho; Bart L Clarke; Gregory A Clines; Juliet E Compston; Matthew T Drake; Beatrice J Edwards; Murray J Favus; Susan L Greenspan; Ross McKinney; Robert J Pignolo; Deborah E Sellmeyer Journal: J Bone Miner Res Date: 2016-01 Impact factor: 6.741
Authors: Dennis M Black; Jane A Cauley; Rachel Wagman; Kristine Ensrud; Howard A Fink; Teresa A Hillier; Li-Yung Lui; Steven R Cummings; John T Schousboe; Nicola Napoli Journal: J Bone Miner Res Date: 2017-07-18 Impact factor: 6.741
Authors: Amanda L Stuart; Sharon L Brennan-Olsen; Julie A Pasco; Amelia G Betson; Kara L Holloway-Kew; Sarah M Hosking; Lana J Williams Journal: Arch Osteoporos Date: 2018-04-14 Impact factor: 2.617
Authors: Robert B Conley; Gemma Adib; Robert A Adler; Kristina E Åkesson; Ivy M Alexander; Kelly C Amenta; Robert D Blank; William Timothy Brox; Emily E Carmody; Karen Chapman-Novakofski; Bart L Clarke; Kathleen M Cody; Cyrus Cooper; Carolyn J Crandall; Douglas R Dirschl; Thomas J Eagen; Ann L Elderkin; Masaki Fujita; Susan L Greenspan; Philippe Halbout; Marc C Hochberg; Muhammad Javaid; Kyle J Jeray; Ann E Kearns; Toby King; Thomas F Koinis; Jennifer Scott Koontz; Martin Kužma; Carleen Lindsey; Mattias Lorentzon; George P Lyritis; Laura Boehnke Michaud; Armando Miciano; Suzanne N Morin; Nadia Mujahid; Nicola Napoli; Thomas P Olenginski; J Edward Puzas; Stavroula Rizou; Clifford J Rosen; Kenneth Saag; Elizabeth Thompson; Laura L Tosi; Howard Tracer; Sundeep Khosla; Douglas P Kiel Journal: J Bone Miner Res Date: 2019-12-01 Impact factor: 6.741
Authors: Dennis M Black; Ian R Reid; Steven Boonen; Christina Bucci-Rechtweg; Jane A Cauley; Felicia Cosman; Steven R Cummings; Trisha F Hue; Kurt Lippuner; Peter Lakatos; Ping Chung Leung; Zulema Man; Ruvie Lou Maria Martinez; Monique Tan; Mary Ellen Ruzycky; Guoqin Su; Richard Eastell Journal: J Bone Miner Res Date: 2012-02 Impact factor: 6.741
Authors: Young Hoon Jo; Bong Gun Lee; Hee Soo Kim; Joo Hak Kim; Chang Hun Lee; Sung Jae Kim; Wan Sun Choi; Jae Ho Lee; Kwang Hyun Lee Journal: J Korean Med Sci Date: 2018-02-12 Impact factor: 2.153